...
首页> 外文期刊>BMC Genomics >Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures
【24h】

Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures

机译:估计多形性胶质母细胞瘤患者的生存时间并鉴定已鉴定的microRNA特征

获取原文
           

摘要

Background Though glioblastoma multiforme (GBM) is the most frequently occurring brain malignancy in adults, clinical treatment still faces challenges due to poor prognoses and tumor relapses. Recently, microRNAs (miRNAs) have been extensively used with the aim of developing accurate molecular therapies, because of their emerging role in the regulation of cancer-related genes. This work aims to identify the miRNA signatures related to survival of GBM patients for developing molecular therapies. Results This work proposes a support vector regression (SVR)-based estimator, called SVR-GBM, to estimate the survival time in patients with GBM using their miRNA expression profiles. SVR-GBM identified 24 out of 470 miRNAs that were significantly associated with survival of GBM patients. SVR-GBM had a mean absolute error of 0.63?years and a correlation coefficient of 0.76 between the real and predicted survival time. The 10 top-ranked miRNAs according to prediction contribution are as follows: hsa-miR-222, hsa-miR-345, hsa-miR-587, hsa-miR-526a, hsa-miR-335, hsa-miR-122, hsa-miR-24, hsa-miR-433, hsa-miR-574 and hsa-miR-320. Biological analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway on the identified miRNAs revealed their influence in GBM cancer. Conclusion The proposed SVR-GBM using an optimal feature selection algorithm and an optimized SVR to identify the 24 miRNA signatures associated with survival of GBM patients. These miRNA signatures are helpful to uncover the individual role of miRNAs in GBM prognosis and develop miRNA-based therapies.
机译:背景尽管多形性胶质母细胞瘤(GBM)是成人中最常见的脑恶性肿瘤,但由于预后差和肿瘤复发,临床治疗仍面临挑战。最近,由于微RNA在调节癌症相关基因中的新兴作用,微RNA(miRNA)已广泛用于开发精确的分子疗法。这项工作旨在鉴定与GBM患者生存相关的miRNA标记,以开发分子疗法。结果这项工作提出了一种基于支持向量回归(SVR)的估算器,称为SVR-GBM,以使用其miRNA表达谱估算GBM患者的生存时间。 SVR-GBM在470个miRNA中鉴定出24个与GBM患者的存活率显着相关。 SVR-GBM的平均绝对误差为0.63?年,真实生存时间与预测生存时间之间的相关系数为0.76。根据预测贡献的10个排名最高的miRNA如下:hsa-miR-222,hsa-miR-345,hsa-miR-587,hsa-miR-526a,hsa-miR-335,hsa-miR-122, hsa-miR-24,hsa-miR-433,hsa-miR-574和hsa-miR-320。使用京都市基因与基因组百科全书(KEGG)途径对已鉴定的miRNA进行的生物学分析显示了它们对GBM癌症的影响。结论拟议的SVR-GBM使用最佳特征选择算法和优化的SVR来识别与GBM患者生存相关的24个miRNA特征。这些miRNA签名有助于揭示miRNA在GBM预后中的个体作用,并开发基于miRNA的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号